Donated plasma is processed into specialized medical products used to treat bleeding disorders, autoimmune conditions, and severe infections. It is not transfused directly into patients but purified into therapies that target specific health needs.
Plasma is the liquid component of blood that carries proteins, antibodies, and clotting factors. After donation, it undergoes rigorous testing and fractionation-breaking it into individual components based on molecular weight and solubility. This allows manufacturers to isolate specific proteins for therapeutic use.
The American Red Cross reports that over 1 million plasma donations were collected annually in the U.S. as of 2023, with most going toward manufacturing treatments for rare and chronic conditions. Not all plasma is used the same way-some becomes immunoglobulins, others factor concentrates, and some supports research into new drugs.
Donors give plasma through apheresis, a process where blood is drawn, the plasma separated using a centrifuge, and the remaining blood cells returned. Each session takes 60-90 minutes and occurs every 28 days. The FDA requires donors to meet specific health criteria, including normal liver function and absence of certain infectious agents.
After collection, plasma is tested for HIV, hepatitis B and C, syphilis, and West Nile virus. Only units passing all safety screens proceed to processing. Each batch is quarantined until test results confirm negative status.
Once cleared, plasma enters fractionation. This step separates proteins by size and charge. For example, immunoglobulin G (IgG)-a key antibody-can be isolated and concentrated into IVIG (intravenous immunoglobulin) therapy. A single unit of plasma may yield multiple therapeutic fractions, maximizing utility.
Plasma-derived products treat over 50 conditions, including primary immunodeficiency, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP). These therapies are not synthetic-they rely on human plasma because the immune system produces unique protein structures that lab-made versions cannot replicate.
Factor VIII and IX concentrates are essential for hemophilia patients. Without these, even minor injuries can cause uncontrolled bleeding. According to the National Hemophilia Foundation, nearly 100% of hemophilia treatment relies on plasma-derived clotting factors, though recombinant versions are increasingly available.
During the 2020 pandemic, convalescent plasma-plasma from recovered COVID-19 patients-was studied as a potential treatment. While later trials showed limited benefit, the effort highlighted plasma's role in rapid-response medicine. Some centers still use it off-label for immunocompromised patients with prolonged viral shedding.
| Product Type | Primary Use | Source Requirement | Example Condition Treated |
|---|---|---|---|
| IVIG | Immune support | High IgG concentration | Primary immunodeficiency |
| Factor VIII | Blood clotting | Low viral load | Hemophilia A |
| Albumin | Volume expansion | Stable protein structure | Severe burns, shock |
| Alpha-1 antitrypsin | Lung protection | High purity | Genetic emphysema |
One unit of plasma can produce up to four different therapeutic products. For example, a single batch processed in 2022 yielded 120 vials of IVIG, 80 factor VIII units, and 40 albumin bags-all from 1,000 mL of plasma.
Many assume donated plasma is directly transfused into patients. That's incorrect. Unlike whole blood donations, plasma is never used as a direct replacement. Its proteins are too complex and variable for safe infusion without purification.
Another misconception is that plasma donation is a form of "blood selling." While donors receive compensation-typically $20-$50 per session-it's not a sale. The payment covers time and travel, not the plasma itself. The FDA prohibits commercialization of human tissues, so all plasma goes to licensed manufacturers under strict regulations.
A lesser-known fact: plasma is not recycled. Once processed, the leftover components-like lipids and waste proteins-are discarded. The recovery rate for usable proteins is around 60%, meaning roughly 40% of the original plasma volume is lost in processing.
In 2021, a 7-year-old boy in Oregon developed sudden weakness in his legs after a viral infection. Doctors diagnosed him with CIDP, a rare disorder where the immune system attacks peripheral nerves. Standard treatments failed. He was then given monthly infusions of IVIG derived from pooled plasma donations.
Over six months, he received 24 doses-each containing plasma from over 1,000 donors. His strength improved. By year-end, he walked without assistance. The IVIG had restored his nerve function by modulating immune activity.
This case illustrates how plasma donation enables precision medicine. The product wasn't made in a lab-it came from real people who gave their plasma voluntarily. The treatment wouldn't exist without a steady supply of safely collected plasma.
Eligible donors can give at certified plasma centers like Grifols, CSL Behring, or BioLife. Each center follows FDA guidelines and tracks donor history to prevent over-donation. Donors must be at least 18, weigh over 110 pounds, and pass a health screening.
After donation, plasma is shipped in temperature-controlled containers to central processing facilities. It is frozen within 24 hours to preserve protein integrity. From there, it moves to fractionation plants, where it's split into components using chromatography and precipitation methods.
Manufacturers must register with the FDA and submit annual reports. The agency audits production sites every two years. Any contamination or deviation triggers recall procedures. In 2022, a single batch was recalled due to a labeling error, but no patients were harmed.
When you donate plasma, you're not giving blood-you're contributing a biological raw material. Your donation doesn't go directly to a patient, but it becomes part of a chain that saves lives. If you're considering donating, understand that your contribution is not a one-time act-it's a recurring input into a medical system that depends on consistent supply.
Donated plasma powers therapies that extend and improve lives. It's not just a medical resource-it's a foundation of modern biopharmaceuticals. Understanding what happens to it after donation reveals the quiet impact of each donation.